New Approaches to Cocaine Abuse Medications (A) - 6

This study has been completed.

First Received: September 20, 1999 Last Updated: June 23, 2005 History of Changes

Sponsor:	National Institute on Drug Abuse (NIDA)
Collaborator:	New York State Psychiatric Institute
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000271

Purpose

The purpose of this study is to measure the effect of desipramine in cocaine abusers selected for major depression or dysthymia.

Condition	Intervention	Phase
Cocaine-Related Disorders Substance-Related Disorders	Drug: Desipramine	Phase II

Study Type:	Interventional
Study Design:	Treatment
Official Title:	New Approaches to Cocaine Abuse Medications (A)

Resource links provided by NLM:

MedlinePlus related topics: Depression

Drug Information available for: Desipramine Desipramine hydrochloride

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Side effects
Craving
Drug use
Retention
Depression

Estimated Enrollment:	0
Study Start Date:	January 1995

Eligibility

Ages Eligible for Study:	18 Years to 60 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000271

Locations

United States, New York
Research Foundation for Mental Hygiene
New York, New York, United States, 10032

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

New York State Psychiatric Institute

Investigators

Principal Investigator:

Herbert Kleber, M.D.

New York State Psychiatric Institute

More Information

No publications provided

Study ID Numbers:	NIDA-09236-6, P50-09236-6
Study First Received:	September 20, 1999
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00000271 History of Changes
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Cocaine-Related Disorders
Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Disease
Adrenergic Agents
Molecular Mechanisms of Pharmacological Action
Adrenergic Uptake Inhibitors
Physiological Effects of Drugs
Psychotropic Drugs
Disorders of Environmental Origin

Enzyme Inhibitors
Desipramine
Pharmacologic Actions
Antidepressive Agents, Tricyclic
Pathologic Processes
Mental Disorders
Therapeutic Uses
Substance-Related Disorders
Central Nervous System Agents
Antidepressive Agents

ClinicalTrials.gov processed this record on November 27, 2009